Figure 2

Differential activation of MAPK pathways by CD95 in cells resistant to oxaliplatin-induced cell death. To determine the contribution of oxaliplatin-induced CD95 to the activation of A) p42/44 MAPK, B) p38 MAPK signaling pathways and to the activation of C) NF-κB (p65 NLS), cells were treated with oxaliplatin (10 μM), the CD95 agonistic antibody CH11 (150 ng/ml) or the combination of both for 48 hours, and the protein levels determined by Western blot.